scholarly journals Rare Incidence of Acute Liver Injury with Potassium Para-Aminobenzoate Introduction

2018 ◽  
Vol 12 (2) ◽  
pp. 230-233 ◽  
Author(s):  
Layth Al Attar ◽  
Wiliam Kilgore
Keyword(s):  
Liver Injury ◽  
Side Effect ◽  
Liver Enzymes ◽  
Acute Liver Injury ◽  
Peyronie’S Disease ◽  
Quadrant Pain ◽  
Elevated Liver Enzymes ◽  
Peyronie's Disease ◽  
New Treatment ◽  
The Many

Acute liver injury is an alarming condition, as it may lead to a devastating outcome. Of the many causes of acute liver injury, review of medications is crucial to identifying the cause of the injury. Some commonly used medications may unpredictably be the underlying cause of liver injury. We present a case of Peyronie’s disease treated with potassium para-aminobenzoate that developed acute liver injury. After starting the new treatment, the patient complained of right upper quadrant pain. He was found to have elevated liver enzymes. The condition resolved after stopping potassium para-aminobenzoate use. We report a potassium para-aminobenzoate side effect of liver injury that can be managed conservatively.

scholarly journals Disulfiram-Induced Acute Liver Injury

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Lucas Ramer ◽  
Matthieu Tihy ◽  
Nicolas Goossens ◽  
Jean-Louis Frossard ◽  
Laura Rubbia-Brandt ◽  
...  
Keyword(s):  
Liver Injury ◽  
Acute Hepatitis ◽  
Fulminant Hepatitis ◽  
Liver Enzymes ◽  
Drug Withdrawal ◽  
Acute Liver Injury ◽  
True Incidence ◽  
Elevated Liver Enzymes ◽  
Severity Of Injury ◽  
Hepatocyte Necrosis

Disulfiram is a drug used to treat alcohol dependence since many years. It interferes with the metabolism of alcohol, may be associated with neurological and dermatological symptoms, and can be hepatotoxic. Due to the frequent coexistent liver test alterations due to alcohol, the true incidence of disulfiram-associated liver injury is unclear and severity of injury may vary from mildly elevated liver enzymes to fulminant hepatitis leading to death. There are several reported cases of disulfiram hepatitis in the literature. Liver histology, when available, demonstrates some degree of portal inflammation with eosinophils and hepatocyte necrosis. We present here a well-documented case of acute hepatitis due to disulfiram with typical histological lesions, favorable outcome following drug withdrawal, and a brief steroid course. The risk of hepatotoxicity should be kept in mind when prescribing disulfiram.

A 27-Year-Old Woman with Right Upper Quadrant Pain and Elevated Liver Enzymes

2010 ◽  
Vol 105 ◽  
pp. S265-S266
Author(s):  
Matthew Ben ◽  
Louis Rotkowitz ◽  
Bradley Gornstein ◽  
Lee Ratner ◽  
Hertl Martin
Keyword(s):  
Liver Enzymes ◽  
Quadrant Pain ◽  
Elevated Liver Enzymes

scholarly journals Clozapine-induced liver injury and pleural effusion

2014 ◽  
Vol 6 (2) ◽  
pp. 36-37
Author(s):  
Joseph P.M. Kane ◽  
Francis A. O'Neill
Keyword(s):  
Pleural Effusion ◽  
Liver Injury ◽  
Liver Enzymes ◽  
Clinical Symptoms ◽  
Acute Liver Injury ◽  
Case Reports ◽  
High Index ◽  
Documented Case ◽  
High Index Of Suspicion ◽  
Symptoms And Signs

Clozapine, whilst associated commonly with a transient and benign increase in liver enzymes, has also been associated with varying presentations of hepatitis in existing case reports. This report describes what we believe to be the first documented case of acute liver injury and pleural effusion associated with clozapine, resolving after cessation of the agent. The case supports existing literature in advocating a high index of suspicion, particularly in the 4-5 weeks following clozapine initiation, when considering nonspecific clinical symptoms and signs.

scholarly journals Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication

2019 ◽  
Vol 12 (11) ◽  
pp. e231741 ◽  
Author(s):  
Chencheng Xie ◽  
Hafez Mohammad Ammar Abdullah ◽  
Mohamed Abdallah ◽  
Erin Quist ◽  
Mumtaz Niazi
Keyword(s):  
Liver Injury ◽  
Liver Enzymes ◽  
Rare Complication ◽  
Assessment Method ◽  
Drug Induced ◽  
Serious Adverse Events ◽  
Drug Induced Liver Injury ◽  
Elevated Liver Enzymes ◽  
Safe Side ◽  
Prolonged Latency

Anastrozole is an aromatase inhibitor that has been used more frequently over the last decade especially for oestrogen receptor-positive breast cancer. It has a relatively safe side effect profile. However, occasionally it has been associated with serious adverse events. Here, we present the case of a 58-year-old woman who presented with significantly elevated liver enzymes 4 years after starting anastrozole. She was not taking any other medications and an extensive workup did not reveal any other cause for her liver injury. The patient’s liver enzymes normalised after discounting the anastrozole. She scored 4 on the updated Roussel Uclaf Causality Assessment Method grading system which was possible for drug-induced liver injury. A review of the literature revealed six prior cases of anastrozole-related liver injury. Anastrozole should be considered as a possible culprit in patients who develop an unexplained acute liver injury.

scholarly journals Preeclampsia Induced Liver Dysfunction Complicated by Disseminated Intravascular Coagulopathy and Placental Abruption: A Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Jordan Myers ◽  
Gary Wu ◽  
Robert E. Shapiro ◽  
Manuel C. Vallejo
Keyword(s):  
Case Report ◽  
Placental Abruption ◽  
Liver Enzymes ◽  
Complex Case ◽  
Review Of The Literature ◽  
Quadrant Pain ◽  
Disseminated Intravascular Coagulopathy ◽  
Elevated Liver Enzymes ◽  
Intravascular Coagulopathy ◽  
Obstetrical Management

A 33-year-old primigravida at 32-week gestation was admitted to labor and delivery complaining of severe right upper quadrant pain and worsening coagulopathy. We report the anesthetic and obstetrical management of a complex case of a parturient with a mixed picture of hemolysis, elevated liver enzymes and low platelets who was delivered under general anesthesia further complicated by Disseminated Intravascular Coagulopathy (DIC) and placental abruption.

Daily tadalafil therapy: A new treatment option for Peyronie’s disease?

2017 ◽  
Vol 16 (3) ◽  
pp. e667
Author(s):  
H.J. Park ◽  
N.C. Park ◽  
T.N. Kim ◽  
J.K. Nam ◽  
D.G. Moon
Keyword(s):  
Treatment Option ◽  
Peyronie’S Disease ◽  
Peyronie's Disease ◽  
New Treatment

scholarly journals The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPARαActivation

PPAR Research ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Wenwen Wang ◽  
Kan Chen ◽  
Yujing Xia ◽  
Wenhui Mo ◽  
Fan Wang ◽  
...  
Keyword(s):  
Liver Injury ◽  
Oleanolic Acid ◽  
Molecular Mechanisms ◽  
Liver Enzymes ◽  
Acute Liver Injury ◽  
Inflammatory Factors ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Anti Inflammatory ◽  
Major Factors

Objective. Previous studies have characterized the hepatoprotective and anti-inflammatory properties of oleanolic acid (OA). This study aimed to investigate the molecular mechanisms of OA hepatoprotection in concanavalin A- (ConA-) induced acute liver injury.Materials and Methods. ConA (20 mg/kg) was intravenously injected to induce acute liver injury in Balb/C mice. OA pretreatment (20, 40, and 80 mg/kg) was administered subcutaneously once daily for 3 consecutive days prior to treatment with ConA; 2, 8, and 24 h after ConA injection, the levels of serum liver enzymes and the histopathology of major factors and inflammatory cytokines were determined.Results. OA reduced the release of serum liver enzymes and inflammatory factors and prevented ConA mediated damage to the liver. OA elevated the expression levels of peroxisome proliferator-activated receptor alpha (PPARα) and decreased the phosphorylation of c-Jun NH2-terminal kinase (JNK).Conclusion. OA exhibits anti-inflammatory properties during ConA-induced acute liver injury by attenuating apoptosis and autophagy through activation of PPARαand downregulation of JNK signaling.

Liver Injury in Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome Measured by Diffusion-Weighted Magnetic Resonance Imaging

2017 ◽  
Vol 35 (08) ◽  
pp. 741-747
Author(s):  
Ambereen Khan ◽  
April Bailey ◽  
Takeshi Yokoo ◽  
Ivan Pedrosa ◽  
Donald McIntire ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Liver Injury ◽  
Hellp Syndrome ◽  
Liver Enzymes ◽  
Resonance Imaging ◽  
Diffusion Weighted ◽  
Elevated Liver Enzymes ◽  
Weighted Magnetic Resonance Imaging ◽  
Adc Map

Objective The objective of this study was to evaluate acute liver injury (ALI) detected by diffusion-weighted magnetic resonance imaging (MRI) and the associated laboratory findings in women with hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome. Study Design This was a retrospective, observational study of women with HELLP syndrome defined by serum aspartate aminotransferase (AST) levels ≥100 U/L and thrombocytopenia with platelets ≤100,000/µL. All women underwent MRI postpartum including diffusion-weighted imaging to estimate the volume of ALI with reconstructed apparent diffusion coefficient (ADC) maps. The ADC map and the volume of ALI were compared with laboratory abnormalities by Spearman's correlation analysis. Results From March 2013 through August 2015, 16 women with HELLP syndrome underwent MRI, and of these, 14 (88%) women had areas of increased signal intensity suggestive of ALI. Their median (range) maximum AST level was 262 (140–1,958) IU/L, and at the time of MRI, AST was 103 (36–1,426) IU/L. Both of these AST levels significantly correlated with ADC map as well as the volume of ALI (both p-values <0.001). Conclusion Women with HELLP syndrome frequently exhibited areas of abnormal diffusion in the liver on diffusion-weighted MRI, suggestive of ALI. The extent of liver injury was significantly correlated with serum AST.

Sign in / Sign up

Export Citation Format

Share Document